J
Jelveh Lameh
Researcher at ACADIA Pharmaceuticals Inc.
Publications - 18
Citations - 1019
Jelveh Lameh is an academic researcher from ACADIA Pharmaceuticals Inc.. The author has contributed to research in topics: Receptor & Agonist. The author has an hindex of 14, co-authored 18 publications receiving 946 citations.
Papers
More filters
Journal ArticleDOI
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.
D. M. Weiner,Herbert Y. Meltzer,Isaac Veinbergs,E. M. Donohue,Tracy A. Spalding,T. T. Smith,Nina Mohell,Scott C. Harvey,Jelveh Lameh,Norman Nash,Kimberly E. Vanover,Roger Olsson,Karuna Jayathilake,Myung A. Lee,Allan I. Levey,Uli Hacksell,Ethan S. Burstein,Robert E. Davis,Mark R. Brann +18 more
TL;DR: The muscarinic receptor agonist activities of NDMC are unique among antipsychotics, and provide a possible molecular basis for the superior clinical effects of clozapine pharmacotherapy.
Journal ArticleDOI
Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist
Kimberly E. Vanover,David M. Weiner,Malath Makhay,Isaac Veinbergs,Luis R. Gardell,Jelveh Lameh,Andria L. Del Tredici,Fabrice Piu,Hans H. Schiffer,Thomas R. Ott,Ethan S. Burstein,Allan K. Uldam,Mikkel B. Thygesen,Nathalie Schlienger,Carl-Magnus A. Andersson,Thomas Son,Scott C. Harvey,Susan B. Powell,Mark A. Geyer,Bo-Ragner Tolf,Mark R. Brann,Robert E. Davis +21 more
TL;DR: ACP-103 is a potent, efficacious, orally active 5-HT2A receptor inverse agonist with a behavioral pharmacological profile consistent with utility as an antipsychotic agent and demonstrates >42.6% oral bioavailability in rats.
Journal ArticleDOI
Activity of opioid ligands in cells expressing cloned mu opioid receptors
TL;DR: These results elucidate the relative activities of a set of opioid ligands at mu opioid receptor and can serve as the initial step in a systematic study leading to understanding of the mode of action of opioidligands at this receptor.
Journal ArticleDOI
Pharmacology of N-desmethylclozapine ☆
Jelveh Lameh,Ethan S. Burstein,Eve Taylor,David M. Weiner,Kimberly E. Vanover,Douglas W. Bonhaus +5 more
TL;DR: This review compares the pharmacological properties of NDMC to those of clozapine and considers whether NDMC, in its own right, might be a superior antipsychotic drug.
Journal ArticleDOI
Pharmacological profiles of opioid ligands at kappa opioid receptors.
TL;DR: These results elucidate the relative activities of a set of opioid ligands at κ-opioid receptor and can serve as the initial step in a systematic study leading to understanding of the mode of action of these opioid ligand at this receptor.